Gencurix

Gencurix

We're going one step ahead with excellent liquid biopsies.

HQ location
Seoul, South Korea
Launch date
Employees
Enterprise value
$91—136m
Company register number
2068657589
Recent deals
  • Edit
Get premium to view all results
DateInvestorsAmountRound
-investor investor investor investor investor investor

€0.0

round
investor

€0.0

round
*

KRW27.0b

Late VC
Total Funding000k
Notes (0)
More about Gencurix
Made with AI
Edit

Gencurix specializes in molecular diagnostics, focusing on early cancer detection and personalized treatment strategies. The company operates in the healthcare sector, serving medical professionals and patients globally. Gencurix's core products include liquid biopsies and genetic tests, such as Geneswell BCT, which are designed to identify cancer at an early stage and tailor treatment plans to individual patients. The business model revolves around the development, production, and distribution of these diagnostic tools, generating revenue through sales to hospitals, clinics, and research institutions. Gencurix aims to improve patient outcomes and quality of life by providing accurate and timely diagnostic information.

Keywords: molecular diagnostics, cancer detection, personalized treatment, liquid biopsy, genetic testing, Geneswell BCT, healthcare, early diagnosis, medical professionals, patient outcomes.

Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.
Book a Demo

Investments by Gencurix

Edit